NewsBite

Pathology

December 2024

Sonic Healthcare chief executive Colin Goldschmidt has made a $700 million investment in Germany.

Sonic Healthcare to buy German lab group for $700m

Pathology giant Sonic Healthcare is buying one of Germany’s top medical lab groups as it seeks to expand its market share in Europe.

  • Michael Smith

September 2024

Australian Clinical Labs is the No.3 player in the pathology market.

Crescent dumps Australian Clinical Lab stake; E&P on ticket

Street Talk understands the private equity firm traded 60.8 million shares in the healthcare group after the market close on Wednesday.

  • Sarah Thompson, Kanika Sood and Emma Rapaport

August 2024

Healius CEO Paul Anderson is restructuring the struggling pathology company

Healius’ net loss doubles as it restructures, sells imaging unit

The pathology group says the sale of its imaging business is “well advanced” as it posted a net loss in line with expectations.

  • Michael Smith

May 2024

Population ageing will increase demand for pathology services.

This routine health test is an investment opportunity

The share prices of pathology companies are below pre-pandemic levels and the world will need more blood tests.

  • Mark Draper

February 2024

Healius chief executive Maxine Jaquet is pushing hard for the federal government to bring indexation to the pathology sector.

Healius flags asset sales and plans to shut some operations

But the country’s second-largest pathology group cannot say what assets are being considered for sale after it recorded a collapse in margins since June 30.

  • Simon Evans
Advertisement

November 2023

Healius chairwoman Jenny Macdonald at the annual meeting on Tuesday.

Healius chairwoman exits without apology for $2b wipeout

Departing Healius chairwoman Jenny Macdonald understands shareholder “frustration” but would not apologise for $2b of value destruction.

  • Simon Evans
Health Minister Mark Butler.

Healius slammed over withheld patient data

Health Minister Mark Butler says test results have been withheld from the My Health Record digital platform since mid-September.

  • Tom McIlroy
Healius big shareholders’ No.1 ask of the new chair is to fix operating performance.

Healius chair’s head on a stick shows investors out of patience

If the healthcare company can’t pull up its socks in the medium term, expect investors to push the board to think about other ways to realise value.

  • Anthony Macdonald
Jenny Macdonald will step down as chairwoman of Healius.

Healius chairwoman exits as ‘no’ vote looms

Proxy votes show Jenny Macdonald would have failed in her re-election campaign for the Healius board, which is being targeted by Tanarra Capital.

  • Simon Evans
The COVID-19 pandemic was a boon for Healius as demand for testing soared.

Healius boss says company’s economics have been upended as wages rise

Maxine Jaquet also cited record rents as she defended the company’s performance against criticism from major investor Tanarra Capital.

  • Simon Evans
Maxine Jaquet became Healius CEO in March.

Wylie’s Tanarra circulates Healius attack letter as shares slide

The valuation of the pathology group crashed following a rights issue at a hefty discount to reduce debt levels and relieve pressure from lenders.

  • Simon Evans
Healius CEO Maxine Jaquet.

Healius preps $200 million equity raising; Barrenjoey on ticket

The company is seeking to raise between $180 million and $200 million, with the shares expected to be offered at about $1.20 apiece. 

  • Sarah Thompson, Kanika Sood and Emma Rapaport
Wyvern Health is set to open an 85-bed private speciality hospital in Sydney’s north.

Wyuna Partners hired for private hospital equity raise

Proceeds will be used to fund an 85-bed private specialty surgical hospital in Sydney’s north.

  • Sarah Thompson, Kanika Sood and Emma Rapaport

October 2023

Healius shares rose sharply during the COVID-19 pandemic. They are now at their lowest level in more than 20 years.

Struggling Healius backs former PE suitor’s bid for board seat

The pathology and radiology group will back a shock new director in a move that shows its investors getting more involved.

  • Anthony Macdonald

July 2023

The competition regulator has a thing for pathology deals, and the latest one is a doozy.

Pathology dream deal a three-headed competition nightmare

Forget the terms of Australian Clinical Labs’ offer for Healius. What is important is what the regulator says about combining the No.2 and No.3 pathology groups.

  • Updated
  • Anthony Macdonald
Advertisement

May 2023

Elizabeth Holmes poses for The New York Times with partner Billy Evans and their two children.

Fraudster Elizabeth Holmes isn’t fooling anyone (but she keeps trying)

The Theranos founder understood that almost everyone – journalists, investors, patients, doctors – can be swayed by a pat narrative.

  • Benjamin Mazer

April 2023

Street Talk.

Pathology brawl heats up as rivals argue finer points

The trickiest M&A deals are often when two industry players are eyeing each other off, but cannot agree on the terms. That’s what’s going on between the No.2 and No.3 players in the pathology sector.

  • Anthony Macdonald

March 2023

<p>

Healius slings ACL bid to Takeovers Panel

The development comes a day after Healius’ largest shareholders, Perpetual and John Wylie’s Tanarra Capital, declined to support ACL’s bid.

  • Updated
  • Elouise Fowler
A combined Healius/ACL would have 42.3 per cent of Australia’s pathology market.

Opportunistic Clinical Labs tries to pull off dream deal with Healius

The window opened for private equity-backed pathology group Australian Clinical Labs - and it jumped.

  • Anthony Macdonald, Sarah Thompson and Kanika Sood

Original URL: https://www.afr.com/topic/pathology-6fj0